The CAR T-Matters project has recently achieved a significant milestone by producing its first large-scale batch of CAR-T cells, totaling around 5 billion viable cells with over 98% CD3+.
The team started with fresh leukapheresis material, isolated 100 million T cells, and performed activation and transduction with a lentivirus encoding a CAR of interest, achieving over 30% CAR+ T cells without additional transduction-enhancing steps. These cells are now being tested for efficacy and safety.
The researchers highlight their excitement about the initial results and plan further improvements, including speeding up the production process and optimizing the T cells’ “stemness” profile.
Stemmatters develops innovative cell therapies focused on T cells for advanced medical applications and is located at Avepark – Science and Technology Park.
